News | April 04, 2011

FDA Gives Complete Response Letter for PET Imaging Agent

April 4, 2011 – The U.S. Food and Drug Administration (FDA) has given a complete response letter to Eli Lilly and its subsidiary, Avid Radiopharmaceuticals, regarding the new drug application (NDA) for Amyvid (florbetapir F 18 injection). Amyvid is a Positron Emission Tomography (PET) imaging agent under investigation for the detection of beta-amyloid plaque in the brains of living patients.

The complete response was primarily focused on the need to establish a reader training program for market implementation that helps to ensure reader accuracy and consistency of interpretations of existing Amyvid scans.

"Lilly and Avid have been engaged in an active and ongoing dialogue with the FDA," said Wei-Li Shao, Lilly brand director for Amyvid. "We remain confident in the data submission package for Amyvid."

Since questions on the reader training program were raised by FDA reviewers late last year, the companies have been working to address these questions and will continue to do so in an ongoing dialogue with the FDA.

For more information: www.lilly.com

Related Content

New U.S. Tariffs on Chinese Goods Include Imaging Equipment
News | Radiology Business | June 15, 2018 | Jeff Zagoudis, Associate Editor
The Office of the U.S. Trade Representative (USTR) released the much-anticipated list of Chinese-manufactured goods...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Geraldine McGinty Elected First Female Chair of American College of Radiology

Image courtesy of the American College of Radiology

News | Radiology Business | May 22, 2018
The American College of Radiology (ACR) Board of Chancellors has elected Geraldine McGinty, M.D., MBA, FACR, as chair....
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
Joint ACR-SIIM Summit to Examine Economics of AI in Healthcare
News | Artificial Intelligence | May 15, 2018
On May 30, 2018, the American College of Radiology (ACR) Data Science Institute (DSI) and the Society for Imaging...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Charles E. Kahn Jr., M.D., M.S., will become editor of the new online journal, Radiology: Artificial Intelligence

Charles E. Kahn Jr., M.D., M.S.

News | Artificial Intelligence | May 02, 2018
The Board of Directors of the Radiological Society of North America (RSNA) announced that Charles E. Kahn Jr., M.D., M....
Overlay Init